OA10189A - Use of indole derivatives as 5htl agonists - Google Patents

Use of indole derivatives as 5htl agonists Download PDF

Info

Publication number: OA10189A
Authority: OA; OAPI
Prior art keywords: indole; ylmethyl; methylaminosulfonylmethyl; treating; ranging
Prior art date: 1993-04-27

Application number

OA60728A

Other languages

English (en)

Inventor

John Eugene Macor

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-04-27

Filing date

1995-10-27

Publication date

1996-12-18

1995-10-27 Application filed by Pfizer filed Critical Pfizer

1996-12-18 Publication of OA10189A publication Critical patent/OA10189A/en

Links

150000002475 indoles Chemical class 0.000 title description 9
239000000556 agonist Substances 0.000 title description 2
229940054051 antipsychotic indole derivative Drugs 0.000 title 1
238000000034 method Methods 0.000 claims abstract description 21
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 17
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 21
208000035475 disorder Diseases 0.000 claims description 20
208000019695 Migraine disease Diseases 0.000 claims description 17
206010027599 migraine Diseases 0.000 claims description 17
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 12
208000019901 Anxiety disease Diseases 0.000 claims description 10
208000030814 Eating disease Diseases 0.000 claims description 10
208000019454 Feeding and Eating disease Diseases 0.000 claims description 10
-1 Methylaminosulfonylmethyl Chemical group 0.000 claims description 10
208000008589 Obesity Diseases 0.000 claims description 10
208000002193 Pain Diseases 0.000 claims description 10
230000036506 anxiety Effects 0.000 claims description 10
235000014632 disordered eating Nutrition 0.000 claims description 10
235000020824 obesity Nutrition 0.000 claims description 10
208000006561 Cluster Headache Diseases 0.000 claims description 9
206010013654 Drug abuse Diseases 0.000 claims description 9
208000018912 cluster headache syndrome Diseases 0.000 claims description 9
208000011117 substance-related disease Diseases 0.000 claims description 9
206010019233 Headaches Diseases 0.000 claims description 8
231100000869 headache Toxicity 0.000 claims description 8
208000007777 paroxysmal Hemicrania Diseases 0.000 claims description 8
230000000862 serotonergic effect Effects 0.000 claims description 8
230000005062 synaptic transmission Effects 0.000 claims description 8
239000003937 drug carrier Substances 0.000 claims description 6
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims description 6
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims description 6
MUCATPAIVYZION-CYBMUJFWSA-N n-methyl-1-[3-[[(2r)-pyrrolidin-2-yl]methyl]-1h-indol-5-yl]methanesulfonamide Chemical compound C12=CC(CS(=O)(=O)NC)=CC=C2NC=C1C[C@H]1CCCN1 MUCATPAIVYZION-CYBMUJFWSA-N 0.000 claims description 6
BWQZTHPHLITOOZ-CQSZACIVSA-N n-methyl-1-[3-[[(2r)-1-methylpyrrolidin-2-yl]methyl]-1h-indol-5-yl]methanesulfonamide Chemical compound C12=CC(CS(=O)(=O)NC)=CC=C2NC=C1C[C@H]1CCCN1C BWQZTHPHLITOOZ-CQSZACIVSA-N 0.000 claims description 5
208000019553 vascular disease Diseases 0.000 claims description 5
206010009094 Chronic paroxysmal hemicrania Diseases 0.000 claims description 4
206010020772 Hypertension Diseases 0.000 claims description 4
239000003826 tablet Substances 0.000 claims description 4
238000002347 injection Methods 0.000 claims description 3
239000007924 injection Substances 0.000 claims description 3
241000792859 Enema Species 0.000 claims description 2
239000002775 capsule Substances 0.000 claims description 2
239000007920 enema Substances 0.000 claims description 2
230000001314 paroxysmal effect Effects 0.000 claims description 2
239000000829 suppository Substances 0.000 claims description 2
241000124008 Mammalia Species 0.000 claims 5
ZXSGHPDKZOVJHJ-UHFFFAOYSA-N 1-(pyrrolidin-2-ylmethyl)indole Chemical compound C1=CC2=CC=CC=C2N1CC1CCCN1 ZXSGHPDKZOVJHJ-UHFFFAOYSA-N 0.000 claims 1
OXHNLMTVIGZXSG-UHFFFAOYSA-N 1-Methylpyrrole Chemical compound CN1C=CC=C1 OXHNLMTVIGZXSG-UHFFFAOYSA-N 0.000 claims 1
229940095399 enema Drugs 0.000 claims 1
MUCATPAIVYZION-UHFFFAOYSA-N n-methyl-1-[3-(pyrrolidin-2-ylmethyl)-1h-indol-5-yl]methanesulfonamide Chemical compound C12=CC(CS(=O)(=O)NC)=CC=C2NC=C1CC1CCCN1 MUCATPAIVYZION-UHFFFAOYSA-N 0.000 abstract 1
BWQZTHPHLITOOZ-UHFFFAOYSA-N n-methyl-1-[3-[(1-methylpyrrolidin-2-yl)methyl]-1h-indol-5-yl]methanesulfonamide Chemical compound C12=CC(CS(=O)(=O)NC)=CC=C2NC=C1CC1CCCN1C BWQZTHPHLITOOZ-UHFFFAOYSA-N 0.000 abstract 1
150000001875 compounds Chemical class 0.000 description 28
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
239000000203 mixture Substances 0.000 description 20
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 17
239000000243 solution Substances 0.000 description 17
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
239000002253 acid Substances 0.000 description 8
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
229940093499 ethyl acetate Drugs 0.000 description 7
235000019439 ethyl acetate Nutrition 0.000 description 7
229910052757 nitrogen Inorganic materials 0.000 description 7
239000000741 silica gel Substances 0.000 description 7
229910002027 silica gel Inorganic materials 0.000 description 7
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
238000005481 NMR spectroscopy Methods 0.000 description 6
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
239000011541 reaction mixture Substances 0.000 description 6
150000003839 salts Chemical class 0.000 description 6
239000003981 vehicle Substances 0.000 description 6
229940073584 methylene chloride Drugs 0.000 description 5
239000007787 solid Substances 0.000 description 5
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
229940079593 drug Drugs 0.000 description 4
239000003814 drug Substances 0.000 description 4
230000000694 effects Effects 0.000 description 4
238000010828 elution Methods 0.000 description 4
239000000284 extract Substances 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
210000001951 dura mater Anatomy 0.000 description 3
239000000843 powder Substances 0.000 description 3
239000012047 saturated solution Substances 0.000 description 3
235000017557 sodium bicarbonate Nutrition 0.000 description 3
229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 3
229960003708 sumatriptan Drugs 0.000 description 3
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
206010015866 Extravasation Diseases 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
QQONPFPTGQHPMA-UHFFFAOYSA-N Propene Chemical compound CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
239000000908 ammonium hydroxide Substances 0.000 description 2
239000002282 antimigraine agent Substances 0.000 description 2
229940125684 antimigraine agent Drugs 0.000 description 2
239000003420 antiserotonin agent Substances 0.000 description 2
238000003556 assay Methods 0.000 description 2
239000002585 base Substances 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
239000012230 colorless oil Substances 0.000 description 2
238000004440 column chromatography Methods 0.000 description 2
229960004132 diethyl ether Drugs 0.000 description 2
230000036251 extravasation Effects 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
239000006260 foam Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000008101 lactose Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
229910052943 magnesium sulfate Inorganic materials 0.000 description 2
235000019341 magnesium sulphate Nutrition 0.000 description 2
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
239000006199 nebulizer Substances 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
239000000018 receptor agonist Substances 0.000 description 2
229940044601 receptor agonist Drugs 0.000 description 2
238000010992 reflux Methods 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011734 sodium Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000007921 spray Substances 0.000 description 2
239000012258 stirred mixture Substances 0.000 description 2
NHGXDBSUJJNIRV-UHFFFAOYSA-M tetrabutylammonium chloride Chemical compound [Cl-].CCCC[N+](CCCC)(CCCC)CCCC NHGXDBSUJJNIRV-UHFFFAOYSA-M 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
210000000427 trigeminal ganglion Anatomy 0.000 description 2
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
RABQRAHLFNGXIK-UHFFFAOYSA-N 1-(4-amino-3-bromophenyl)-n-methylmethanesulfonamide Chemical compound CNS(=O)(=O)CC1=CC=C(N)C(Br)=C1 RABQRAHLFNGXIK-UHFFFAOYSA-N 0.000 description 1
CIWNHTXCBHTWRV-UHFFFAOYSA-N 1-(4-aminophenyl)-n-methylmethanesulfonamide Chemical compound CNS(=O)(=O)CC1=CC=C(N)C=C1 CIWNHTXCBHTWRV-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
235000019489 Almond oil Nutrition 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
101150041968 CDC13 gene Proteins 0.000 description 1
IQIGWMXTWGDQOV-UHFFFAOYSA-N CNS(=O)(=O)CN1C=C(C2=CC=CC=C12)CC1NCCC1 Chemical compound CNS(=O)(=O)CN1C=C(C2=CC=CC=C12)CC1NCCC1 IQIGWMXTWGDQOV-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
241000700198 Cavia Species 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
241001269524 Dura Species 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
208000003098 Ganglion Cysts Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
239000005909 Kieselgur Substances 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
235000019759 Maize starch Nutrition 0.000 description 1
RLJFTICUTYVZDG-UHFFFAOYSA-N Methiothepine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2CC1N1CCN(C)CC1 RLJFTICUTYVZDG-UHFFFAOYSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
240000006711 Pistacia vera Species 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
239000004141 Sodium laurylsulphate Substances 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
208000005400 Synovial Cyst Diseases 0.000 description 1
206010047095 Vascular pain Diseases 0.000 description 1
DSOITGJEUKHAJN-UHFFFAOYSA-N Zinnimidine Chemical compound CC(C)=CCOC1=C(C)C(OC)=C2CNC(=O)C2=C1 DSOITGJEUKHAJN-UHFFFAOYSA-N 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
239000003708 ampul Substances 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
GLBKZCJTDIWDCT-OAHLLOKOSA-N benzyl (2r)-2-(3-ethoxy-3-oxoprop-1-enyl)pyrrolidine-1-carboxylate Chemical compound CCOC(=O)C=C[C@H]1CCCN1C(=O)OCC1=CC=CC=C1 GLBKZCJTDIWDCT-OAHLLOKOSA-N 0.000 description 1
ASNHSGGMNWXBEI-GFCCVEGCSA-N benzyl (2r)-2-formylpyrrolidine-1-carboxylate Chemical compound O=C[C@H]1CCCN1C(=O)OCC1=CC=CC=C1 ASNHSGGMNWXBEI-GFCCVEGCSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
244000309464 bull Species 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229960001714 calcium phosphate Drugs 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229960004424 carbon dioxide Drugs 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
150000003857 carboxamides Chemical class 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
229910052805 deuterium Inorganic materials 0.000 description 1
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
229940042935 dichlorodifluoromethane Drugs 0.000 description 1
229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
201000010099 disease Diseases 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
229940079360 enema for constipation Drugs 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
239000002024 ethyl acetate extract Substances 0.000 description 1
FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000003818 flash chromatography Methods 0.000 description 1
239000012458 free base Substances 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
238000011597 hartley guinea pig Methods 0.000 description 1
210000001308 heart ventricle Anatomy 0.000 description 1
150000004678 hydrides Chemical class 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
238000005462 in vivo assay Methods 0.000 description 1
125000001041 indolyl group Chemical group 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
229960001375 lactose Drugs 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
239000012280 lithium aluminium hydride Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
230000008018 melting Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
WZHJKEUHNJHDLS-QTGUNEKASA-N metergoline Chemical compound C([C@H]1CN([C@H]2[C@@H](C=3C=CC=C4N(C)C=C(C=34)C2)C1)C)NC(=O)OCC1=CC=CC=C1 WZHJKEUHNJHDLS-QTGUNEKASA-N 0.000 description 1
229960004650 metergoline Drugs 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
NVFHCOMYGPNDTO-UHFFFAOYSA-N n-[2-bromo-4-(methylsulfamoylmethyl)phenyl]-2,2,2-trifluoroacetamide Chemical compound CNS(=O)(=O)CC1=CC=C(NC(=O)C(F)(F)F)C(Br)=C1 NVFHCOMYGPNDTO-UHFFFAOYSA-N 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
239000003380 propellant Substances 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
238000000746 purification Methods 0.000 description 1
210000003752 saphenous vein Anatomy 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
201000009032 substance abuse Diseases 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
150000003456 sulfonamides Chemical class 0.000 description 1
239000002511 suppository base Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
238000012360 testing method Methods 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1
IIHPVYJPDKJYOU-UHFFFAOYSA-N triphenylcarbethoxymethylenephosphorane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC(=O)OCC)C1=CC=CC=C1 IIHPVYJPDKJYOU-UHFFFAOYSA-N 0.000 description 1
238000012762 unpaired Student’s t-test Methods 0.000 description 1
230000002792 vascular Effects 0.000 description 1
239000005526 vasoconstrictor agent Substances 0.000 description 1
229940124549 vasodilator Drugs 0.000 description 1
239000003071 vasodilator agent Substances 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Epidemiology (AREA)
Heart & Thoracic Surgery (AREA)
Psychiatry (AREA)
Obesity (AREA)
Hematology (AREA)
Diabetes (AREA)
Child & Adolescent Psychology (AREA)
Anesthesiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Indole Compounds (AREA)

OA60728A 1993-04-27 1995-10-27 Use of indole derivatives as 5htl agonists OA10189A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US5393093A	1993-04-27	1993-04-27

Publications (1)

Publication Number	Publication Date
OA10189A true OA10189A (en)	1996-12-18

Family

ID=21987528

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA60728A OA10189A (en)	1993-04-27	1995-10-27	Use of indole derivatives as 5htl agonists

Country Status (29)

Country	Link
EP (1)	EP0696194B1 (pl)
JP (1)	JP2922307B2 (pl)
KR (1)	KR960701636A (pl)
CN (3)	CN1509713A (pl)
AP (1)	AP486A (pl)
AT (1)	ATE222492T1 (pl)
AU (1)	AU689469B2 (pl)
BG (1)	BG61898B1 (pl)
BR (1)	BR9406435A (pl)
CA (1)	CA2161533C (pl)
CO (1)	CO4230093A1 (pl)
CZ (1)	CZ290416B6 (pl)
DE (1)	DE69431201T2 (pl)
DK (1)	DK0696194T3 (pl)
ES (1)	ES2180573T3 (pl)
HU (1)	HU222488B1 (pl)
IL (1)	IL109376A (pl)
MX (1)	MX9403088A (pl)
NO (1)	NO308236B1 (pl)
NZ (1)	NZ263614A (pl)
OA (1)	OA10189A (pl)
PL (1)	PL175156B1 (pl)
PT (1)	PT696194E (pl)
RO (1)	RO117760B1 (pl)
RU (1)	RU2132683C1 (pl)
SG (1)	SG43951A1 (pl)
SK (1)	SK283353B6 (pl)
WO (1)	WO1994025023A1 (pl)
ZA (1)	ZA942805B (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5559246A (en) *	1990-10-15	1996-09-24	Pfizer Inc.	Indole derivatives
US5545644A (en) *	1990-10-15	1996-08-13	Pfizer Inc.	Indole derivatives
US5578612A (en) *	1990-10-15	1996-11-26	Pfizer Inc.	Indole derivatives
US5607951A (en) *	1990-10-15	1997-03-04	Pfizer Inc	Indole derivatives
US5559129A (en) *	1990-10-15	1996-09-24	Pfizer Inc	Indole derivatives
CA2169179C (en) *	1993-08-31	2000-02-29	John E. Macor	5-arylindole derivatives
GB9417310D0 (en) *	1994-08-27	1994-10-19	Pfizer Ltd	Therapeutic agents
ATE224388T1 (de) *	1994-10-12	2002-10-15	Pfizer Res & Dev	Indolderivate zur behandlung von migräne
GB9424471D0 (en) *	1994-12-03	1995-01-18	Pfizer Ltd	Treatment of emesis
GB9510223D0 (en) *	1995-05-20	1995-07-19	Pfizer Ltd	Therapeutic agent
US5945118A (en) *	1995-09-29	1999-08-31	Pfizer Inc	Indole derivative for the treatment of migraine
US5773015A (en) *	1996-11-27	1998-06-30	Elizabeth Arden Co., Division Of Conopco, Inc.	Method for controlling skin oils and grease
GB9706089D0 (en) *	1997-03-24	1997-05-14	Scherer Ltd R P	Pharmaceutical composition
US5994352A (en) *	1998-11-13	1999-11-30	Pfizer Inc.	5-arylindole derivatives
ES2199086B1 (es) *	2002-07-31	2005-06-01	Cepa Schwarz Pharma Sl	Nuevos derivados de cicloalcanodionas, procedimiento para su preparacion y sus aplicaciones farmacologicas.
CN115380028A (zh) *	2020-02-04	2022-11-22	明德赛特制药公司	用于治疗cns病症的作为血清素能致幻剂的3-吡咯烷-吲哚衍生物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2091562C (en) *	1990-10-15	2001-03-27	John Eugene Macor	Indole derivatives useful in psychotherapeutics
GB9102579D0 (en) *	1991-01-24	1991-03-27	Glaxo Group Ltd	Compositions
GB9103770D0 (en) *	1991-02-22	1991-04-10	Glaxo Group Ltd	Chemical compounds

1994
- 1994-04-07 AP APAP/P/1994/000633A patent/AP486A/en active
- 1994-04-21 IL IL10937694A patent/IL109376A/xx not_active IP Right Cessation
- 1994-04-22 ZA ZA942805A patent/ZA942805B/xx unknown
- 1994-04-25 CO CO94016790A patent/CO4230093A1/es unknown
- 1994-04-26 WO PCT/IB1994/000079 patent/WO1994025023A1/en not_active Ceased
- 1994-04-26 RU RU95120093/14A patent/RU2132683C1/ru not_active IP Right Cessation
- 1994-04-26 CN CNA011046600A patent/CN1509713A/zh active Pending
- 1994-04-26 NZ NZ263614A patent/NZ263614A/en unknown
- 1994-04-26 JP JP6524076A patent/JP2922307B2/ja not_active Expired - Fee Related
- 1994-04-26 CN CN94191935A patent/CN1121689A/zh active Pending
- 1994-04-26 CA CA002161533A patent/CA2161533C/en not_active Expired - Fee Related
- 1994-04-26 SK SK1332-95A patent/SK283353B6/sk unknown
- 1994-04-26 ES ES94912048T patent/ES2180573T3/es not_active Expired - Lifetime
- 1994-04-26 SG SG1996006766A patent/SG43951A1/en unknown
- 1994-04-26 AU AU64360/94A patent/AU689469B2/en not_active Ceased
- 1994-04-26 DE DE69431201T patent/DE69431201T2/de not_active Expired - Fee Related
- 1994-04-26 DK DK94912048T patent/DK0696194T3/da active
- 1994-04-26 CN CNA021506892A patent/CN1515252A/zh active Pending
- 1994-04-26 PT PT94912048T patent/PT696194E/pt unknown
- 1994-04-26 RO RO95-01860A patent/RO117760B1/ro unknown
- 1994-04-26 HU HU9503089A patent/HU222488B1/hu not_active IP Right Cessation
- 1994-04-26 EP EP94912048A patent/EP0696194B1/en not_active Expired - Lifetime
- 1994-04-26 CZ CZ19952802A patent/CZ290416B6/cs not_active IP Right Cessation
- 1994-04-26 BR BR9406435A patent/BR9406435A/pt not_active Application Discontinuation
- 1994-04-26 KR KR1019950704678A patent/KR960701636A/ko not_active Ceased
- 1994-04-26 AT AT94912048T patent/ATE222492T1/de not_active IP Right Cessation
- 1994-04-26 PL PL94311266A patent/PL175156B1/pl unknown
- 1994-04-27 MX MX9403088A patent/MX9403088A/es unknown
1995
- 1995-10-25 BG BG100093A patent/BG61898B1/bg unknown
- 1995-10-26 NO NO954287A patent/NO308236B1/no not_active IP Right Cessation
- 1995-10-27 OA OA60728A patent/OA10189A/en unknown

Also Published As

Publication number	Publication date
RO117760B1 (ro)	2002-07-30
DE69431201D1 (de)	2002-09-26
AP9400633A0 (en)	1994-04-30
ES2180573T3 (es)	2003-02-16
EP0696194B1 (en)	2002-08-21
HU9503089D0 (en)	1995-12-28
IL109376A (en)	2000-10-31
NO954287D0 (no)	1995-10-26
IL109376A0 (en)	1994-07-31
JPH08504829A (ja)	1996-05-28
WO1994025023A1 (en)	1994-11-10
SG43951A1 (en)	1997-11-14
NZ263614A (en)	1998-02-26
BG61898B1 (bg)	1998-09-30
SK133295A3 (en)	1997-01-08
CO4230093A1 (es)	1995-10-19
NO954287L (no)	1995-10-26
SK283353B6 (sk)	2003-06-03
MX9403088A (es)	1997-02-28
CZ9502802A3 (en)	1996-04-17
CN1509713A (zh)	2004-07-07
BG100093A (bg)	1996-04-30
PL311266A1 (en)	1996-02-05
KR960701636A (ko)	1996-03-28
CA2161533A1 (en)	1994-11-10
DK0696194T3 (da)	2002-10-07
ATE222492T1 (de)	2002-09-15
HU222488B1 (hu)	2003-07-28
AP486A (en)	1996-04-16
DE69431201T2 (de)	2002-12-05
BR9406435A (pt)	1996-01-09
CA2161533C (en)	1998-08-04
EP0696194A1 (en)	1996-02-14
ZA942805B (en)	1995-10-23
NO308236B1 (no)	2000-08-21
AU6436094A (en)	1994-11-21
CN1515252A (zh)	2004-07-28
AU689469B2 (en)	1998-04-02
PL175156B1 (pl)	1998-11-30
CZ290416B6 (cs)	2002-07-17
JP2922307B2 (ja)	1999-07-19
RU2132683C1 (ru)	1999-07-10
PT696194E (pt)	2002-11-29
HUT73670A (en)	1996-09-30
CN1121689A (zh)	1996-05-01

Publication	Publication Date	Title
US6512002B2 (en)	2003-01-28	Methods of treatment for premature ejaculation in a male
AU625192B2 (en)	1992-07-02	Piperazine compounds
RU2351588C2 (ru)	2009-04-10	Производные n-фенил(пиперидин-2-ил)метил-бензамида и их применение в терапии
US20020037886A1 (en)	2002-03-28	Muscarinic agonists
EP0696194B1 (en)	2002-08-21	Use of indole derivatives as 5ht1 antagonists
JPH09508137A (ja)	1997-08-19	セロトニンアゴニストおよびアンタゴニストとしての４−インドール誘導体
JPH08333363A (ja)	1996-12-17	インドール誘導体
JPWO1994014769A1 (ja)	1995-02-02	Ｎ−置換インドール誘導体
KR0183396B1 (ko)	1999-05-01	3-아릴카르보닐-1-아미노알킬-1h-인돌류,이를 함유하는 항녹내장 조성물 및 이의 제조방법
JPH10501819A (ja)	1998-02-17	ある種のアミノメチルフェニルイミダゾール誘導体：新しいクラスのドーパミン受容体サブタイプ特異的リガンド
WO1994025023A9 (en)	1995-10-05	Use of indole derivatives as 5ht1 antagonists
TWI250873B (en)	2006-03-11	Ophthalmic compositions for treating ocular hypertension
WO1998027089A1 (en)	1998-06-25	5-alkyl indole compounds as 5-ht1d-like ligands
JPH02167280A (ja)	1990-06-27	ラクタム誘導体
NO176398B (no)	1994-12-19	Analogifremgangsmåte for fremstilling av terapeutisk aktive 2,3-dihydro-1-(pyridinylamino)-indoler
AU673747B2 (en)	1996-11-21	Use of N-(pyridinyl)-1H-indole-1-amines for the preparation of a medicament for the treatment of obsessive-compulsive disorders
CA2213241C (en)	2001-07-10	Indole derivative for the treatment of migraine
JPS6335570A (ja)	1988-02-16	ヘテロ環式化合物
US5945118A (en)	1999-08-31	Indole derivative for the treatment of migraine
JPH07503240A (ja)	1995-04-06	３‐アリールインドールおよび１‐アリールインダゾール誘導体の精神病の治療のための使用
JPH02180822A (ja)	1990-07-13	医薬
TW300225B (pl)	1997-03-11
JPH03223286A (ja)	1991-10-02	医薬品